Business Magnate Elon Musk is the Subject of Former President Trump's Tale Regarding a Tycoon Receiving a "Fatal Blow"
In a dramatic turn of events, Trump's latest action involves an executive order, presumably aimed at reducing the cost of drugs for American citizens. But, as usual, Trump's announcement was not without his signature declarative storytelling. He regaled the crowd with a yarn about a top-tier business tycoon, whom sources suspect could well be Elon Musk.
The mysterious mogul in question is described as a "wealthy, neurotic, genius businessman," tipping the scales and heavily medication-dependent, commonly referred to as "fat shot drug." The billionaire entrepreneur, according to Trump, complained about the steep difference in drug prices between London and New York. In London, the drug cost him only $88, while in the Big Apple, he had to fork over a staggering $1,300.
Amidst the speculation, social media users eagerly probed the AI chatbot Grok to shed light on the enigma. Grok's verdict? It's likely that Trump was talking about Elon Musk. Musk's reputation as a weight loss drug user and his standing as a renowned entrepreneur bolster Grok's hypothesis. Musk’s global travels also support the argument of price discrepancies in drug costs. However, it's worth noting that Trump's tales can be over-exaggerated, leaving room for uncertainty.
Musk himself has admitted to using an Ozempic competitor, Mounjaro, for weight loss. Like Ozempic, Mounjaro is a GLP-1 inhibitor, initially marketed to manage type 2 diabetes but has since become a popular tool for weight loss. Remarkably, the price of this drug varies significantly between the US and other international markets. Last year, Senator Bernie Sanders put Novo Nordisk, the manufacturer of Ozempic, on the spot, questioning why the drug costs $92 per month in the UK and an eye-watering $1,349 a month in the States.
During the heated Congressional hearing, Sanders voiced his disapproval, labeling the price markups a "serious moral issue." He also pointed out that other manufacturers could produce a generic version of the drug and sell it for less than $100 a month. Even more striking is Sanders's assertion that he managed to pressure Novo Nordisk's CEO to commit to working with pharmacy benefit managers to lower drug prices for Americans. At present, Trump's executive order seems to pale in comparison to Sanders's achievements.
- The future of artificial Intelligence (AI) was used in speculation as social media users questioned an AI chatbot, Grok, about the identity of a business tycoon newly mentioned by President Trump.
- In the tech world, Elon Musk has been touted as a leading contender for the mysterious billionaire entrepreneur whose drug costs vastly differ between London and New York.
- In the realm of health and wellness, Musk admitted to using Mounjaro, a weight loss drug similar to Ozempic, which has a substantial price disparity between the US and other countries.
- On the political front, Senator Bernie Sanders has been vocal about this price gap, criticizing drug manufacturers and advocating for policy changes, such as the production of generic drugs and partnerships with pharmacy benefit managers to lower drug prices.
- In the general news, Sanders's recent achievements in pressuring Novo Nordisk, the manufacturer of Ozempic, to reduce drug prices for Americans have overshadowed Trump's latest executive order for reducing drug costs.
- Science and technology have a significant impact on policy and legislation, as demonstrated by the growing concern over the high costs of healthcare, including medical conditions management and weight-management drugs like Ozempic and Mounjaro.
